相关实验视频
Updated: Jul 27, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.7K
收费类受体4 炎症前景对多克索鲁比诱导的心脏毒性
Natticha Sumneang1,2, Pongpan Tanajak3, Thura Tun Oo4
1Department of Medical Science, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Molecules (Basel, Switzerland)
|June 10, 2023
概括
德克索鲁比 (Dox) 化疗会导致心脏损伤,部分是通过托尔类受体4 (TLR4) 信号传递和心脏炎症. 准TLR4可能为预防Dox诱导的心脏毒性提供新的策略.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 多克索鲁比 (Dox) 是一种重要的化疗剂,但由于心脏毒性,其使用受到限制.
- 由于Dox诱导的心脏毒性机制尚不完全理解,缺乏具体的治疗指南.
- 心脏炎症被认为是Dox诱导心脏毒性的关键因素.
研究的目的:
- 审查证据,将托尔类受体4 (TLR4) 信号通路与Dox诱导的心脏毒性联系起来.
- 讨论TLR4信号对心脏炎症和随后心脏毒性的影响.
- 探索针对TLR4的潜在治疗策略,以减轻Dox引起的心脏毒性.
主要方法:
- 对调查多克索鲁比对心脏影响的研究进行了全面的文献综述.
- 对心脏炎症模型中的托尔类受体4 (TLR4) 信号通路的研究分析.
- 综合来自多种多克斯诱导心脏毒性模型的证据.
主要成果:
- 托尔类受体4 (TLR4) 信号通路显然参与了Dox诱导的心脏炎症.
- TLR4激活显著促进了Dox诱导的心脏毒性的发展和进展.
- 证据支持TLR4介导的炎症和多克索鲁比引起的心脏损伤之间存在强烈的相关性.
结论:
- TLR4信号通路在多克索鲁比诱导的心脏炎症中发挥着关键作用.
- 了解TLR4的作用对于开发针对Dox引起的心脏毒性的向疗法至关重要.
- 准TLR4为未来的治疗干预提供了一个有希望的途径,以保护化疗期间的心脏.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:30Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
29
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
29
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469